Q-omics provides the consensus-scored ANGPTL8 profile across patient tissues and cancer cell-line models. ANGPTL8 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ANGPTL8 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, ANGPTL8 RNA expression shows 12,631 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, COAD, and THYM as cancer lineages where ANGPTL8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANGPTL8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANGPTL8 survival associations across molecular data types. ANGPTL8 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (2) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANGPTL8 RNA expression–survival associations across cancer types. High ANGPTL8 expression shows unfavorable associations in KIRC, LGG and KICH, but favorable associations in BRCA, SARC and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ANGPTL8 RNA expression.
This table summarizes ANGPTL8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 4. The strongest signals are observed in KICH for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ANGPTL8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANGPTL8 shows lower tumor expression in KICH, BRCA, UCEC and CHOL and higher tumor expression in COAD and KIRC. The COAD box plot shows higher ANGPTL8 RNA expression in tumor versus normal tissue (log2 FC = +0.345, t-test p < 0.001).
This table shows molecular features associated with ANGPTL8 in patient tissues and cancer cell lines. In patient samples, ANGPTL8 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ANGPTL8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BONE and SKIN.
